Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | HPGD | P15428 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | LCK | P06239 | 1/20 | 0.44 |
| ▸ | PRKACA | P17612 | 1/20 | 0.44 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.44 |
| ▸ | PRKACG | P22612 | 1/20 | 0.44 |
| ▸ | PRKACB | P22694 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.44 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.44 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4054601 | 0.87 | KDM4E (0.48) | ALDH1A1HPGDKDM4ERAB9AHIF1A | |
| SCHEMBL4050665 | 0.86 | HPGD (0.52) | ALDH1A1HPGDKDM4ERAB9AHIF1A | |
| SCHEMBL4225177 | 0.85 | ALDH1A1 (0.56) | ALDH1A1HPGDKDM4ERAB9AHIF1A | |
| SCHEMBL4046732 | 0.84 | TERT (0.47) | ALDH1A1HPGDKDM4ERAB9AHIF1A | |
| SCHEMBL4047633 | 0.83 | TERT (0.47) | ALDH1A1HPGDKDM4ERAB9AHIF1A | |
| SCHEMBL4511530 | 0.83 | HPGD (0.54) | ALDH1A1HPGDKDM4ERAB9AHIF1A | |
| SCHEMBL4047642 | 0.83 | PARP1 (0.53) | ALDH1A1HPGDKDM4ERAB9AHIF1A | |
| SCHEMBL4215004 | 0.81 | HTT (0.53) | ALDH1A1HPGDKDM4ERAB9AHIF1A | |
| SCHEMBL4225788 | 0.81 | ALDH1A1 (0.48) | ALDH1A1HPGDKDM4ERAB9AHIF1A | |
| SCHEMBL4051794 | 0.79 | HPGD (0.58) | ALDH1A1HPGDKDM4ERAB9AHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090298858-A1 | POTENT PARP INHIBITORS | ABBOTT LABORATORIES (US) | 2009-12-03 | — | — | US | claimed |
| CN-101506214-A | Pyrazoloquinazolinones as PARP inhibitors | ABBOTT LAB (US) | 2009-08-12 | — | — | CN | claimed |
| EP-2069351-A2 | PYRAZOLOQUINAZOLINONES AS PARP INHIBITORS | Abbott Laboratories (US) | 2009-06-17 | — | — | EP | claimed |
| US-20080015182-A1 | Potent PARP Inhibitors | ABBOTT LABORATORIES | 2008-01-17 | — | — | US | claimed |
| WO-2007149907-A2 | PYRAZOLOQUINAZOLINONES AS PARP INHIBITORS | ABBOTT LABORATORIES (US) | 2007-12-27 | — | — | WO | claimed |
| EP-2069351-B1 | PYRAZOLOQUINAZOLINONES AS PARP INHIBITORS | ABBVIE INC (US) | 2015-10-28 | — | — | EP | disclosed |
| US-8183250-B2 | Potent PARP inhibitors | ABBOTT LABORATORIES (US) | 2012-05-22 | — | — | US | disclosed |
| US-20090298858-A1 | POTENT PARP INHIBITORS | ABBOTT LABORATORIES (US) | 2009-12-03 | — | — | US | disclosed |
| CN-101506214-A | Pyrazoloquinazolinones as PARP inhibitors | ABBOTT LAB (US) | 2009-08-12 | — | — | CN | disclosed |
| EP-2069351-A2 | PYRAZOLOQUINAZOLINONES AS PARP INHIBITORS | Abbott Laboratories (US) | 2009-06-17 | — | — | EP | disclosed |
| US-20080015182-A1 | Potent PARP Inhibitors | ABBOTT LABORATORIES | 2008-01-17 | — | — | US | disclosed |
| WO-2007149907-A2 | PYRAZOLOQUINAZOLINONES AS PARP INHIBITORS | ABBOTT LABORATORIES (US) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298858-A1 | POTENT PARP INHIBITORS | PARP1, PARP2, PARP3 | ALDH1A1 282/4885HPGD 392/4885KDM4E 515/4885 |
| US-20080015182-A1 | Potent PARP Inhibitors | PARP1, PARP2, PARP3 | ALDH1A1 282/4885HPGD 392/4885KDM4E 515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.